My Tysabri Diary...wonderful news!

TYSABRI® RECEIVES APPROVAL IN NEW ZEALAND

TYSABRI® RECEIVES APPROVAL IN NEW ZEALAND FOR THE

TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS

Auckland, New Zealand – 27th September 2007 – Biogen Idec NZ Limited and Elan Corporation, plc (NYSE: ELN) today announced that TYSABRI® (natalizumab 300mg) had been registered as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (MS) to delay the progression of physical disability and to reduce the frequency of relapse.

The registration was based on a submission that included TYSABRI two-year Phase III clinical trial data and findings from a comprehensive safety evaluation. An estimated 4000 people in New Zealand are affected by MS.

“Today marks an important step forward for the New Zealand MS patient community,” said Eric Fidelin, Managing Director of Biogen Idec New Zealand. “TYSABRI represents one of the most significant advances in MS treatment in nearly 10 years and provides patients living with this disabling disease an important new therapeutic choice.”

###

ABOUT TYSABRI

TYSABRI is a treatment approved for relapsing forms of MS in the United States and relapsing-remitting MS in the European Union. According to data that have been published in the New England Journal of Medicine, after two years, TYSABRI treatment led to a 68% relative reduction (p<0.001)>

Oh my gosh, I'm so happy for them....YeeeeeeeHaaaaaaaw!

(((hugs)))
Love, Lauren :)
A very proud member of www.MSpatientsforchoice.org